Matthew D. Hellmann
0000-0002-2670-9777
Publication & Citation Trends
Publications
0 total
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
Cited by 1
Semantic Scholar
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors OA
Cited by 2
Semantic Scholar
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
Cited by 111
Semantic Scholar
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors OA
Cited by 43
Semantic Scholar
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors OA
Cited by 117
Semantic Scholar
Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy OA
Cited by 45
Semantic Scholar
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non–Small-Cell Lung Cancer
Cited by 24
Semantic Scholar
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Cited by 14
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(484)
Lung Cancer Treatments and Mutations
(424)
Cancer Genomics and Diagnostics
(224)
Lung Cancer Research Studies
(209)
Lung Cancer Diagnosis and Treatment
(95)
Affiliations
AstraZeneca (United Kingdom)
Loyola University Medical Center
Hudson Institute
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center